Biomerieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast-cancer patients.
This test, based on emerging biomarkers, will be intended for use in adjuvant and metastatic breast-cancer settings, subject to regulatory approvals.
The test, to be co-funded by the two companies, will will be developed by Biomerieux's global R+D team, including its subsidiary, Biotheranostics.
The Biotheranostics team has expertise in molecular oncology diagnostics, with its Theros Cancertype ID test for identifying metastatic cancers of uncertain or unknown origin and Theros Breast Cancer Index (SM) test for predicting breast-cancer-recurrence risk.
Following clinical evaluation, the test will be launched by Biotheranostics in its CLIA-certified laboratory, after which an in-vitro diagnostic kit will be developed by Biomerieux and introduced to the global market.
